Johnson & Johnson Inc. (NYSE: JNJ) shares are trading lower Tuesday after a U.S. bankruptcy court in Texas rejected subsidiary Red River Talc's request to approve its prepackaged bankruptcy plan.
Following the worst quarterly performance for U.S. stocks in over two years, caution dominated Wall Street as investors awaited details on the tariff plans expected from the Trump administration on Wednesday.
Shares of multinational healthcare company Johnson & Johnson (NYSE:JNJ)
fell 5.6% in the morning session after a judge in Texas rejected the company's third attempt to use bankruptcy as a legal shield against lawsuits alleging its talcum powder products caused ovarian cancer.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends.
The brief revival in U.S. factory activity vanished in March as input prices shot up at the fastest pace since mid-2022, raising red flags about eroding profit margins, cost pass-through risks and strained supply chains as the U.S.
Value stocks are outperforming flashy growth rivals due to market uncertainty, making value-based ETFs a good bet for steady income and diversification.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 11.1%. This drop was worse than the S&P 500’s 4% decline.
